Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Acta Cardiologica
- Vol. 74 (2), 100-107
- https://doi.org/10.1080/00015385.2018.1455947
Abstract
Background: Signs and symptoms of volume overload are the most frequent reason for hospital admission in acute heart failure (AHF). Diuretics are mainstay treatment, but their optimal type and dose regimen remain unclear, especially in patients with cardiorenal syndrome. Methods: This prospective study aimed to include 80 AHF patients with volume overload and cardiorenal syndrome. Through a 2 x 2 factorial design, patients were randomised towards (1) combinational treatment with acetazolamide and low-dose loop diuretics versus high-dose loop diuretics; and (2) open-label oral spironolactone 25mg OD given upfront versus at discharge. Here reported are the results of the spironolactone treatment arm after complete follow-up of 34/80 patients (since the study was stopped because of slow recruitment). The primary study end-point was incident hypokalaemia (5.5mmol/L). Results: Serum potassium derangements were numerically less frequent in the upfront versus discharge spironolactone group, yet this result was underpowered due to incomplete study recruitment (hyperkalaemia: 6% vs. 11%; hypokalaemia: 13% vs. 28%, respectively; p-value = .270). Natriuresis after 24 h was higher in the upfront vs. discharge spironolactone group (314 +/- 142 vs. 200 +/- 91mmol/L, respectively; p-value 1/4 .010). Relative change in plasma NT-proBNP level after 72 h was similar among both groups (-16 +/- 29% vs. -5 +/- 45%, respectively; p value = .393), with no difference in all-cause mortality (p-value 1/4 .682) or the combination of all-cause mortality and heart failure readmission (p-value = .799). Discussion: Spironolactone use upfront in AHF patients at high risk for cardiorenal syndrome is safe and increases natriuresis.This publication has 24 references indexed in Scilit:
- Frequency and Predictors of Hyperkalemia in Patients ≥60 Years of Age With Heart Failure Undergoing Intense Medical TherapyThe American Journal of Cardiology, 2012
- Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?Circulation: Heart Failure, 2012
- Diuretic Strategies in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Sodium Retention in Heart Failure and CirrhosisCirculation: Heart Failure, 2009
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJama-Journal Of The American Medical Association, 2007
- How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?Journal of Cardiac Failure, 2004
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitorThe American Journal of Cardiology, 1993
- Aldosterone in Congestive Heart Failure: Analysis of Determinants and Role in Sodium RetentionAmerican Journal of Nephrology, 1991